Edwards Mitral Valve Replacement System SAPIEN M3 Receives CE Mark

Edwards Portfolio Extended To Include Both Mitral Replacement And Repair Options

“We believe [the SAPIEN M3] launch alongside PASCAL and EVOQUE will help support the company’s target of $2bn in transcatheter mitral and tricuspid therapies sales by 2030,” noted analysts from Leerink Partners.

heart valve

Edwards Lifesciences announced the CE marking of the SAPIEN M3 mitral valve replacement system for the treatment of patients with moderate to and severe mitral regurgitation on 14 April.

The regulatory approval makes Edwards the “only company providing a transcatheter portfolio that includes both replacement and repair treatment options...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Approvals

More from Policy & Regulation